Related Experiment Video
Updated: Sep 15, 2025
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Targeting of bowel tissue by fully human antibodies cross-reactive with human and mouse GPA33 antigen
Genki Hichiwa1, Abdur Rafique2, Asaki Nagashima2
1Department of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University, Tottori, Japan; Chromosome Engineering Research Center, Tottori University, Tottori, Japan.
Abstract:
Monoclonal antibodies are indispensable therapeutic agents for various diseases, including cancer, autoimmune disorders, and infectious diseases. Glycoprotein A33 (GPA33), a cell surface antigen highly expressed in colorectal cancer, provides a compelling therapeutic target; however, the species-specificity of anti-GPA33 antibodies has limited their utility in preclinical models, thus inhibiting their development. Here, we generated and characterized fully human, cross-reactive anti-GPA33 antibodies using phage-display technology with transchromosomic antibody-producing animals. The resulting single-chain variable fragment and single-chain variable fragment crystallizable antibodies exhibited high specificity and affinity for both human and mouse GPA33. In vivo imaging confirmed their targeted retention in mouse intestine, indicating their potential for developing targeted therapeutic approaches. The ability of these antibodies to recognize both human and murine GPA33 enhances their applicability in preclinical models, improving their translation from experimental to clinical applications. These results highlight the feasibility of developing cross-reactive, fully human antibodies and support the advancement of GPA33-targeted diagnostic approaches and the exploration of novel therapeutic strategies for relevant gastrointestinal diseases.
Insights
Researchers developed fully human, cross-reactive antibodies targeting Glycoprotein A33 (GPA33) for colorectal cancer. These antibodies work in both human and mouse models, advancing targeted therapies and diagnostics.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Monoclonal antibodies are key therapeutics for cancer and autoimmune diseases.
- Glycoprotein A33 (GPA33) is a promising colorectal cancer target, but species-specific antibodies hinder preclinical development.
- Developing cross-reactive antibodies is crucial for effective preclinical modeling and therapeutic translation.
Purpose of the Study:
- To generate and characterize fully human, cross-reactive anti-GPA33 antibodies.
- To overcome species-specificity limitations of existing anti-GPA33 antibodies.
- To facilitate preclinical testing and advance GPA33-targeted therapies for gastrointestinal diseases.
Main Methods:
- Phage-display technology was employed to create antibodies.
- Transchromosomic antibody-producing animals were utilized.
- Characterization included specificity, affinity, and in vivo imaging studies.
Main Results:
- Fully human, cross-reactive single-chain variable fragment (scFv) and scFv crystallizable (Fc) antibodies targeting GPA33 were successfully generated.
- These antibodies demonstrated high specificity and affinity for both human and mouse GPA33.
- In vivo imaging confirmed targeted retention in mouse intestines, validating their potential for in vivo applications.
Conclusions:
- The developed antibodies are effective against both human and murine GPA33, enhancing preclinical model utility.
- This work demonstrates the feasibility of creating cross-reactive, fully human antibodies.
- The findings support the advancement of GPA33-targeted diagnostics and novel therapeutic strategies for gastrointestinal cancers.
